// +author:v agarwal +author:agarwal 
var _ajax_res = {
  hits: 26,

  first: 0,

  results: [

{userid:"Subramanyam.Vemulpad", "articletype":"article","pages":"181-192","author":"V R Subramanyam, D S Agarwal","year":"1983","title":"Transferability and localisation of genetic determinants of staphylococcal drug resistance","month":"","journal":"Indian Journal of Medical Research","publisher":"","volume":"78","number":"2","note":"TY  - JOUR xD;Cited By: 0, Export Date: 15 September 05, Source: Scopus","tags":"","booktitle":"","editor":"","abstract":"","address":"","school":"","issn":"","doi":"","isi":"","pubmed":"","key":"Subramanyam1983","howpublished":"","urllink":"","refid":121}
,

{userid:"Subramanyam.Vemulpad", "articletype":"article","pages":"820-8.","author":"V R Subramanyam, D S Agarwal","year":"1982","title":"Multiple drug resistant staphylococci in hospital practice","month":"","journal":"Indian J Med Res","publisher":"","volume":"76","number":"","note":"","tags":"Antibiotics\/pharmacology,Drug Resistance, Microbial,Staphylococcus aureus\/*drug effects\/genetics","booktitle":"","editor":"","abstract":"","address":"","school":"","issn":"","doi":"","isi":"","pubmed":"","key":"Subramanyam1982b","howpublished":"http:\/\/www.ncbi.nlm.nih.gov\/htbin-post\/Entrez\/query?db=m&form=6&dopt=r&uid=7169237","urllink":"http:\/\/www.ncbi.nlm.nih.gov\/htbin-post\/Entrez\/query?db=m&form=6&dopt=r&uid=7169237","refid":123}
,

{userid:"Subramanyam.Vemulpad", "articletype":"article","pages":"21-22.","author":"U K Baveja, V R Subramanyam, D S Agarwal","year":"1981","title":"Detection of penicillinase production by four methods.","month":"","journal":"Indian Journal of Pathology & Microbiology","publisher":"","volume":"24","number":"","note":"","tags":"","booktitle":"","editor":"","abstract":"","address":"","school":"","issn":"","doi":"","isi":"","pubmed":"","key":"Baveja1981","howpublished":"","urllink":"","refid":125}
,

{userid:"manivannan.sethuraman", "refid":102,"repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Shear Strength Capacity of Wide Reinforced Concrete Beam with Shear Steel Plates","year":"2013","author":"Suhaib Jamal Ali & V. C. Agarwal","journal":"International Journal of Civil, Structural, Environmental and Infrastructure Engineering Research and Development (IJCSEIERD)","volume":"3","number":"5","pages":"189-196","month":"December","doi":"","pubmed":"","pdflink":"http:\/\/www.tjprc.org\/view_archives.php?year=2013&id=11&jtype=2&page=6","urllink":"","abstract":"Wide reinforced concrete beams have been used in buildings to reducereinforcement congestion and floor heights\r\nfor required headroom. The beamin most of these cases is wider than that of the supporting columns.Consequently their\r\nshear capacity might be effected and differ from that ofconventional beams. This project report presents the test results of\r\nfour widebeam specimens in which their shear performances were studied. Theinfluence of the support widths (100% of\r\nthe beam width), the arrangement offlexural reinforcement across the beam width, and the presence of shearreinforcement in the forms of third specimens consist of concrete with steelplate and control beam conventional beam were investigated. The test setupwas made similar for all the specimens, one pointed load were on the beamwidth, the load put at distance column (300mm*300mm) from the center ofsupport, therefore, the specimen control faed in diagonal tension shear. Butother specimens failed in flexural corporation. The results showed that widebeam with plate has no effect on the shear strength of concrete and theinfluence of concentrating the flexural reinforcement within the support widthhas no significant effect on the shear strength of concrete.","note":"","tags":"Distance Column (300mm*300mm), ACI (318-11), Flexural Reinforcement","weight":102}
,

{userid:"Subramanyam.Vemulpad", "articletype":"article","pages":"77-81.","author":"V R Subramanyam, R C Mishra, U K Baveja, D S Agarwal","year":"1982","title":"Bacteriological and clinical evaluation of amoxycillin, a new semisynthetic penicillin.","month":"","journal":"The Antiseptic","publisher":"","volume":"79","number":"","note":"","tags":"","booktitle":"","editor":"","abstract":"","address":"","school":"","issn":"","doi":"","isi":"","pubmed":"","key":"Subramanyam1982a","howpublished":"","urllink":"","refid":122}
,

{userid:"martin.krahn", "articletype":"article","pages":"388-390","author":"Satish V Khadilkar, Rakesh K Singh, Pankaj Agarwal, Martin Krahn, Nicolas Levy","year":"2008","title":"Twenty-two year follow-up of an Indian family with dysferlinopathy-clinical, immunocytochemical, western blotting and genetic features.","month":"Jul\/Sep","journal":"Neurol India","publisher":"","volume":"56","number":"3","note":"","tags":"Adult,Blotting, Western,Family Health,Humans,Immunohistochemistry,India,Longitudinal Studies,Male,Membrane Proteins,Muscle Proteins,Muscle, Skeletal,Muscular Dystrophies, Limb-Girdle","booktitle":"","editor":"","abstract":"Long-term observations over a period of 22 years in an Indian family with primary dysferlinopathy are recorded, defining phenotypic variability. In the propositus, the dystrophy began distally in the tibialis anterior muscles, before involving the gastrocnemius. Transient painful calf hypertrophy, followed by calf wasting was observed. The proximal lower and upper limbs weakened after three to four years. The younger sibling presented with the proximo-distal phenotype. Both patients showed very high creatine kinase values early into the illness. Disease progression was slow. The younger sibling lost ambulation 14 years after onset, while the elder one remains ambulatory 22 years into the illness. Muscle biopsy showed dystrophic features and absence of dysferlin. Monocyte western blotting confirmed absence of dysferlin. Genetic analysis detected a heterozygous mutation in Exon 54 [c.6124C>T] in the DYSF gene. This is the first family with a diagnosis of dysferlinopathy supported by genetic data, reported from India.","address":"","school":"","issn":"0028-3886","doi":"","isi":"","pubmed":"18974570","key":"Khadilkar2008","howpublished":"","urllink":"","refid":12}
,

{userid:"sugathan", "refid":14,"attachment":"","articletype":"article","sectionheading":"","title":"\t\r\nHard photon production in p+197Au reaction at Ep=27 MeV\r\n","year":"1999","author":"D. R. Chakrabarty, V. M. Datar, Y. K. Agarwal, C. V. Baba, M. S. Samant, I. Mazumdar, A. K. Sinha, and P. Sugathan\r\n","journal":"Phys. Rev. C ","volume":"60","number":"","pages":"024606","month":"","doi":"","pubmed":"","pdflink":"","urllink":"","abstract":"\r\n\r\nGamma ray spectra in the range of \u223c8\u201335 MeV have been measured at 45\u00b0, 90\u00b0, and 135\u00b0 in the reaction p+197Au at Ep=27 MeV. The statistical and the nucleon-nucleon bremsstrahlung models fail to describe the data. The direct-semidirect capture model works well for E\u03b3>20 MeV. The possibility of extracting information on the single particle strength distribution in the final nucleus has been illustrated.\r\n","note":"","tags":""}
,

{userid:"amvinodkumar", "articletype":"article","pages":"1902-1908","author":"D O Kataria, A K Sinha, J J Das, N Madhavan, P Sugathan, L T Baby, I Mazumdar, R Singh, C V K Baba, Y K Agarwal, A M Vinodkumar, K M Varier","year":"1997","title":"One- and two-nucleon transfer in the Si-28+Zn-68 system at energies below the Coulomb barrier","month":"OCT","journal":"PHYSICAL REVIEW C","publisher":"","volume":"56","number":"4","note":"","tags":"","booktitle":"","editor":"","abstract":"Excitation functions for one-and two-nucleon transfer in Si-28 + Zn-68 system have been measured at energies below the Coulomb barrier. The experiment was carried out by detecting the forward recoiling targetlike nuclei using the recoil mass separator, HIRA. With a pulsed beam, the time-of-flight of the recoils was measured and used to resolve the M\/q ambiguity. This enabled the determination of the two-nucleon transfer yields. The role of one-and two-nucleon transfer in the sub-barrier fusion cross-section enhancement has been investigated. It turns out that the coupling of the positive e-value two-neutron transfer channel results in a significant contribution to the enhancement. Coupling to both the transfer and the inelastic channels is able to explain the observed enhancement.","address":"","school":"","issn":"0556-2813","doi":"10.1103\/PhysRevC.56.1902","isi":"","pubmed":"","key":"ISI:A1997YC72900025","howpublished":"","urllink":"","refid":66,"weight":66}
,

{userid:"kris.kowdley", "articletype":"article","pages":"1973-1982","author":"Fred Poordad, Christophe Hezode, Roger Trinh, Kris V Kowdley, Stefan Zeuzem, Kosh Agarwal, Mitchell L Shiffman, Heiner Wedemeyer, Thomas Berg, Eric M Yoshida, Xavier Forns, Sandra S Lovell, Barbara Da Silva-Tillmann, Christine A Collins, Andrew L Campbell, Thomas Podsadecki, Barry Bernstein","year":"2014","title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.","month":"May","journal":"The New England journal of medicine","publisher":"","volume":"370","number":"21","note":"","tags":"Adult,Aged,Anilides,Antiviral Agents,Carbamates,Drug Resistance, Viral,Drug Therapy, Combination,Female,Genotype,Hepacivirus,Hepatitis C, Chronic,Humans,Liver Cirrhosis,Logistic Models,Macrocyclic Compounds,Male,Middle Aged,Recurrence,Ribavirin","booktitle":"","editor":"","abstract":"Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450\/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults with HCV genotype 1 infection and compensated cirrhosis.","address":"","school":"","issn":"1533-4406","doi":"10.1056\/NEJMoa1402869","isi":"","pubmed":"24725237","key":"Poordad2014","howpublished":"","urllink":"","refid":8,"weight":8}
,

{userid:"kris.kowdley", "refid":"477","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.","year":"2018","author":"Tarik Asselah, Kris V Kowdley, Neddie Zadeikis, Stanley Wang, Tarek Hassanein, Yves Horsmans, Massimo Colombo, Filipe Calinas, Humberto Aguilar, Victor de Ledinghen, Parvez S Mantry, Christophe Hezode, Rui Tato Marinho, Kosh Agarwal, Frederik Nevens, Magdy Elkhashab, Jens Kort, Ran Liu, Teresa I Ng, Preethi Krishnan, Chih-Wei Lin, Federico J Mensa","journal":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","volume":"16","number":"3","pages":"417-426","month":"Mar","doi":"10.1016\/j.cgh.2017.09.027","pubmed":"28951228","pdflink":"","urllink":"","abstract":"Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents that are effective against all major HCV genotypes, with shorter treatment duration, are needed to reduce disease burden. Glecaprevir (an NS3\/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) have a high barrier to resistance and synergistic antiviral activity. We evaluated the safety and efficacy of 8 and 12 weeks' treatment with glecaprevir\/pibrentasvir in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis in 3 separate phase 3 trials.","note":"","tags":"","weight":477,"publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"1542-7714","isi":"","key":"Asselah2018","howpublished":""}
  ]
}

;
ajaxResultsLoaded(_ajax_res);